FDA Recalls Dofetilide Antiarrhythmic Drug for Manufacturing Deviations
Accord Healthcare is recalling Dofetilide antiarrhythmic capsules due to manufacturing compliance deviations identified during FDA inspection. The recall affects approximately 113,003 bottles distributed in the U.S., Puerto Rico, and Canada.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall without reported illnesses or injuries and no specific identified safety hazard. Manufacturing compliance deviations are treated as precautionary, warranting Moderate severity.
Plain-English summary
Accord Healthcare, Inc. is recalling Dofetilide 500 mcg antiarrhythmic capsules distributed in the United States, Puerto Rico, and Canada. Approximately 113,003 bottles of the affected product have been distributed. The recall was initiated following an FDA inspection that identified manufacturing practice deviations at the producing facility. Affected batches have expiration dates ranging from February 2023 through May 2025. Patients currently taking Dofetilide should contact their healthcare provider to discuss their prescription and available treatment alternatives.
The recalled product
- Product
- DOFETILIDE (DOFETILIDE)
- Brand
- DOFETILIDE
- Manufacturer
- Accord Healthcare, Inc.
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: P2101582
- P2101661
- P2101482
- P2101686
- Exp. Date 2/28/2023
- P2102581
- P2102598
- Exp. Date 4/30/2023
- P2103623
- P2103653
- P2103670
- Exp. Date 5/31/2023
- P2104463
- P2104385
- P2104386
- P2104472
- P2104709
- P2104714
- Exp. Date 6/30/2023
- P2200797
UPCs (1)
- 316729492126
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · DOFETILIDE
- ModerateDofetilide Capsules Recalled Due to Out-of-Specification Content Uniformity
FDA (Drugs) · 2023-08-16
- HighDofetilide antiarrhythmic prescription drug recalled for manufacturing deviations
FDA (Drugs) · 2023-03-08
- ModeratePrescription Drug Dofetilide Recalled Due to Manufacturing Compliance Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27